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Abstract
G protein-coupled receptor regulation of gene transcription primarily occurs through the
phosphorylation of transcription factors by MAPKs. This requires transduction of an activating signal
via scaffold proteins that can ultimately determine the outcome by binding signaling kinases and
adapter proteins with effects on the target transcription factor and locus of activation. By investigating
these mechanisms, we have elucidated how pituitary gonadotrope cells decode an input GnRH signal
into coherent transcriptional output from the LH β-subunit gene promoter. We show that GnRH
activates c-Src and multiple members of the MAPK family, c-Jun NH2-terminal kinase 1/2,
p38MAPK, and ERK1/2. Using dominant-negative point mutations and chemical inhibitors, we
identified that calcium-dependent proline-rich tyrosine kinase 2 specifically acts as a scaffold for a
focal adhesion/cytoskeleton-dependent complex comprised of c-Src, Grb2, and mSos that
translocates an ERK-activating signal to the nucleus. The locus of action of ERK was specifically
mapped to early growth response-1 (Egr-1) DNA binding sites within the LH β-subunit gene proximal
promoter, which was also activated by p38MAPK, but not c-Jun NH2-terminal kinase 1/2. Egr-1 was
confirmed as the transcription factor target of ERK and p38MAPK by blockade of protein expression,
transcriptional activity, and DNA binding. We have identified a novel GnRH-activated proline-rich
tyrosine kinase 2-dependent ERK-mediated signal transduction pathway that specifically regulates
Egr-1 activation of the LH β-subunit proximal gene promoter, and thus provide insight into the
molecular mechanisms required for differential regulation of gonadotropin gene expression.
THE MAPKS ARE A FAMILY of evolutionarily conserved serine/threonine kinases that
transmit externally derived signals regulating cell growth, division, gene transcription,
differentiation, and apoptosis (1). There are a plethora of mechanisms by which G protein-
coupled receptors (GPCRs) activate MAPKs; this underpins the fundamental nature of this
receptor-mediated effect in cell physiology (for review see Refs. 2 and 3). GPCR activation of
several types of G proteins (Gαs, Gαo, Gαq/11, Gαi) can initiate ERK (a MAPK isoform)
activation, yet there is a radiation of the signal transduction process distal to G protein activation
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(for review see Ref. 4). Signals subsequently generated by second messenger-dependent
protein kinases [protein kinase A and protein kinase C (PKC) (5)], cross talk-activated
epidermal growth factor receptor (EGFR) (6) or heterodimerized integrin receptors [involving
focal adhesion kinase (FAK); or proline-rich tyrosine kinase 2 (Pyk2) activation; (7)] all
eventually converge at the level of the canonical ERK-activating cascade (4). We and others
have demonstrated that generic GPCR-mediated ERK activation is reliant upon the formation
of complex multiprotein superstructures (8-11), and insights have recently been generated with
respect to the nature of the catalytic activity of ERK depending upon which specific proteins
constitute the ERK-activating superstructure (4,12).
The GPCR, GnRH receptor (GnRHR), controls the differential synthesis and release of LH
and FSH from bihormonal anterior pituitary gonadotrope cells, by binding the hypothalamic
peptide, GnRH. Stimulation of the GnRHR triggers an intracellular second messenger-
signaling cascade that increases gene expression of the common α-glycoprotein subunit and
hormone-specific LH and FSH β-subunits primarily via activation of different MAPK isoforms
(13-19). GnRHR-mediated activation of ERK is dependent upon the functionality of focal
adhesion-linked proteins (9) and highlights that several distinct mechanisms of ERK activation
can exist because GnRH-mediated ERK activation can also occur through activation of PKC
(5) and reportedly through an EGFR-cross talk mechanism (20). The identities of the key
scaffold proteins required for GnRH-induced MAPK activation are unknown, but there is
increasing evidence that protein scaffolds and cross talk between different signaling pathways
do control the outcome of GnRHR signaling (21,22).
Instead, there has been considerable focus on gonadotropin gene promoter regulatory DNA
elements required for pituitary-specific basal expression, especially how these combine and
synergize with GnRH-regulatory DNA elements (reviewed in Ref. 23). Briefly, the LH β-
subunit gene promoter encodes GnRH-activating regions comprised of DNA binding sites for
homeodomain factors (Pitx1 and Otx-related), nuclear receptor steroidogenic factor-1 (SF-1),
Sp1, and GnRH-induced early growth response-1 (Egr-1), which form an activating complex
(Ref. 24 and references therein). These factors are obligate for LH β-subunit gene expression
(25-27) and may also be regulated by GnRH (28-30) by as yet undefined mechanisms. Indeed,
the link between GnRH induction of MAPK isoforms, multiprotein activating complex, and
the transcriptional target that combine to subsequently activate LH β-subunit gene expression
has not been elucidated.
Here we report, using the α-glycoprotein subunit-expressing αT3-1 (31) and LH-expressing
LβT2 (32) gonadotrope cell lines, a novel GnRH-induced, Pyk2-mediated, ERK-signaling
pathway that is conserved between these cell lines. We demonstrate GnRH activation of this
pathway, other MAPK family members [p38MAPK and c-Jun NH2-terminal kinase 1/2 (JNK)]
and the soluble tyrosine kinase c-Src, and map these to distinct GnRH-activation sites on the
LH β-subunit gene promoter. A direct link between Egr-1 transcriptional activation, ERK and
p38MAPK signaling, and regulation of promoter activity was established. This advances the
understanding of how the GnRH signal is transduced from the plasma membrane to the nucleus,
identifies Pyk2 as an ERK-scaffold protein important for mediating GnRH regulation of LH
β-subunit gene expression, and elucidates how GnRH-MAPK signaling regimes are decoded
into gene expression via Egr-1.
RESULTS
GnRH-Induced MAPK Activation in Gonadotrope Cells
Adding a physiological dose of 10 nM GnRH to αT3-1 or LβT2 cells rapidly elevated the levels
of active phosphorylated ERK1/2. Activation was measured at 1 min and could still be
measured at 90 min (Fig. 1, A-C). Because this prolonged activation is atypical of GPCRs, the
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stimulation of c-Src and other MAPK family members by GnRH was investigated and
compared with ERK1/2. GnRH elevated levels of active-JNK1/2, active-p38MAPK, and c-Src
(Fig. 2, A-D). Comparison of panels A-D indicated that all active-MAPKs and c-Src were
measurable by 5 min. Given that active-ERK1/2 rapidly responded to GnRH stimulation and
that ERK activation has been extensively studied in GPCR signaling, we focused on the mode
of activation of ERK in the context of gonadotrope cell lines.
Putative Roles of EGFR, Ca2+, and Cytoskeleton in GnRH-Induced ERK1/2 Activation
The stimulation of MAPK isoforms by many GPCRs has been reported to occur via an
epidermal growth factor receptor (EGFR) transactivation mechanism (33). GnRH-mediated
ERK1/2 activation in the two gonadotrope cell lines was resistant to chemical inhibition of the
EGFR intrinsic tyrosine kinase with AG1478 pretreatment (Fig. 3). However in both αT3-1
and LβT2, EGF (10 ng/ml, 10 min)-mediated tyrosine phosphorylation of the EGFR and
subsequent activation of ERK1/2 was abrogated by AG1478 pretreatment (Fig. 3). In addition,
it was evident that there was no significant GnRH-induced increase in EGFR tyrosine
phosphorylation. We next assessed the GnRH-induced activation of ERK1/2 in both αT3-1
and LβT2 cells in the presence of chemical agents that have been demonstrated to inhibit other
GPCR-mediated ERK1/2 activation signals. As demonstrated in Fig. 4 GnRH-induced ERK1/2
activation was sensitive to chelation of intracellular calcium release by 1,2-bis (2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid acetoxymethyl ester (BAPTA-AM) and to
inhibition of PKC with both depletion of endogenous PKC by phorbol12-myristate-13-acetate
chronic exposure and by inhibition of PKC activity by Ro-31–8220 preincubation. GnRH-
induced ERK1/2 activation was also sensitive to disruption of active cytoskeletal dynamics
with cytochalasin-D and latrunculin-B. Using a panel of tyrosine kinase inhibitors, it was
demonstrated that although resistant to inhibition of the EGFR kinase, the GnRH-induced
ERK1/2 activation is sensitive to less specific tyrosine kinase inhibitors, herbimycin-A and c-
Src inhibitor 4-amino-5-(4-cholorophenyl)-7-(t-butyl)pyrazolo[3,4-D]pyrimidine (PP2). The
lack of effect of 10 nM wortmannin demonstrates that the GnRH-induced ERK1/2 activation
was independent of the kinase activity of phosphatidylinositol 3-kinase. Furthermore, using a
100–200 nM concentration of wortmannin has no effect on LH β-subunit gene expression or
activation of ERK [data not shown; (13)]. Considering the novel lack of EGFR-transactivation
dependence of the GnRH-induced ERK1/2 activation and its sensitivity to general tyrosine
kinase inhibition, we next investigated in an unbiased manner the general nature of control of
tyrosine phosphorylation in gonadotrope cells upon GnRH stimulation.
GnRH-Mediated Tyrosine Phosphorylation in αT3-1 and LβT2 Gonadotropes
GnRH stimulation of both the gonadotrope cell lines resulted in the increase in phosphotyrosine
status of several proteins (Fig. 5, panel A, αT3-1; panel B, LβT2). The major protein tyrosine
phosphorylated in response to GnRH was approximately 115 kDa. Using a specific antiserum
to Pyk2, we determined that the approximately 115-kDa protein was indeed the Ca2+-
dependent tyrosine kinase also known as FAK2 or RAFTK. Upon GnRH stimulation there was
a rapid and relatively long-lasting increase in the tyrosine phosphorylation status of specifically
immunoprecipitated Pyk2 (Fig. 5, C-D). We found that expression of the other main focal
adhesion kinase, FAK, was minimal and demonstrated only a minimal elevation of its tyrosine
phosphorylation status (data not shown). We next assessed whether there was a commonality
in Pyk2/ERK1/2 signal sensitivity to our panel of chemical inhibitors. We were specifically
interested in the ERK1/2 signal generation in LβT2 cells as they can functionally synthesize
mature LH in an ERK-dependent manner (13). Compared with the sensitivity to inhibitors of
c-Src, PKC, and EGFR kinase activity, the GnRH-mediated Pyk2 stimulation displayed a
similar pattern to that for ERK1/2 activation, suggesting that the two events may be physically
associated (Fig. 5E). A profound inhibition of Pyk2 activation was also observed after
preincubation with cytochalasin-D and latrunculin-B, further reinforcing the role of focal
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adhesions in the GnRH-mediated ERK1/2 activation. We therefore treated the cells with Arg-
Gly-Asp-Ser (RGDS) tetrapeptides, which have been used extensively to disrupt cytoskeletal
organization in cellular tissues via their capacity to disrupt focal adhesion complexes (7,9).
Preincubation of LβT2 cells with RGDS (1 mM) peptide inhibited the GnRH-induced activation
of both Pyk2 and ERK1/2 (Fig. 6). A similar preincubation with Arg-Gly-Glu-Ser (RGES)
tetrapeptide had no significant effect upon GnRH action. Neither RGDS nor RGES tetrapeptide
had any significant effect upon EGF (10 ng/ml, 10 min)-stimulated ERK1/2 activation.
GnRH-Induced Signaling Protein Complex Assembly at Pyk2
Because we demonstrated a c-Src dependence involved in GnRHR-mediated Pyk2 and ERK1/2
activation, we investigated whether there was signal complex assembly between these two
proteins. GnRH stimulation elevated the relative c-Src content of Pyk2 immunoprecipitates
(Fig. 7). The association was persistent, lasting up to 1 h after GnRH stimulation. Preincubation
with the cytoskeletal disruptors, cytochalasin-D and latrunculin-B, and the tyrosine kinase
inhibitor herbimycin-A all disrupted the ability of GnRH to induce signaling complex assembly
between c-Src and Pyk2. In our experimental paradigm we propose that ERK-activating
complex assembly occurs at the Ca2+-depdendent tyrosine kinase Pyk2 and not at the EGFR;
therefore we demonstrated that GnRH stimulation induced association of Pyk2 with the mSos
binding protein Grb2. GnRH stimulation induced a time-dependent elevation in the relative
Grb2 content of Pyk2 immunoprecipitates (Fig. 7C), and in the reciprocal experiment the
relative Pyk2 content of Grb2 immunoprecipitates also increased (Fig. 7D). We also noted that
the Pyk2 associated with the Grb2 immunoprecipitates was tyrosine phosphorylated in
response to GnRH stimulation (Fig. 7E).
GnRH-Induced Signaling Complex Assembly and ERK1/2 Activation
To demonstrate the role of Pyk2 in ERK activation, we employed point mutants of Pyk2 and
observed their effect on GnRH activation of a cotransfected myc-tagged ERK2.
Overexpression of a kinase inactive Pyk2 mutant (K475A) abrogated the GnRH-induced
activation of the cotransfected myc-tagged ERK2 (Fig. 8). Overexpression of the Y402F
mutant of Pyk2, in which the primary c-Src interacting site is lost, also attenuated the capacity
of GnRH to activate the myc-tagged ERK2. Overexpression of the Y881F mutant of Pyk2, in
which the major Grb2 binding site tyrosine is also mutated, led to a reduction in the ability of
GnRH to activate myc-tagged ERK2. Thus it appears that a productive activation of the Pyk2
intrinsic tyrosine kinase and subsequent protein-protein association with c-Src and Grb2 are
required for GnRH-induced ERK activation. Because we have demonstrated GnRH induces a
Grb2 translocation to tyrosine-phosphorylated Pyk2 we next investigated whether the ERK1/2
activation pathway was Ras dependent. Cotransfecting the myc-tagged ERK2 reporter with a
dominant-negative form of Ras (N17Ras) inhibited GnRH-mediated ERK2 activation (Fig. 8).
Overexpression of a dominant-negative c-Raf (Raf-C4B), the direct downstream effector of
Ras, also inhibited GnRH-induced ERK2 activation. Preincubation of LβT2 cells with the
MAPK kinase (MEK1/2) inhibitor, PD98059, demonstrated that the eventual activation of
ERK1/2 is due to the dual tyrosine-threonine kinase MEK1/2.
GnRH-Induced Nuclear Activation of ERK1/2
LβT2 cells stained for the active form of ERK1/2, in the absence of GnRH agonist in serum-
starvation conditions, demonstrated minimal staining (Fig. 9, panel A, images 1 and 2).
Application of GnRH (10 nM) induced an elevation in the background cytoplasmic staining and
an increase in the appearance of active ERK1/2 in the cell nucleus. With greater time periods
of GnRH stimulation, there was a significant increase in the amount of active ERK1/2 staining
across the entire nucleus but not in the nucleolus (Fig. 9A, images 3-8). Nuclear staining for
active ERK1/2 persisted for up to 120 min and with greater cellular magnification it was noted
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that active ERK1/2 regions became annular in structure within the nucleus (data not shown).
The degree of nuclear active ERK1/2 was significantly attenuated by pretreatment of the cells
with cytochalasin-D or latrunculin-B (Fig. 9B, images 5-8) indicating the important role of
focal adhesions in GnRH-mediated ERK1/2 activation.
Mapping of GnRH Response Elements in the LH β-Subunit Gene Promoter
Having defined GnRH induction and translocation of active ERK1/2, we then examined
possible regulatory targets of this nuclear signaling complex. The −1786 bp of the ovine LH
β-subunit gene promoter is regulated by GnRH in vivo (34); therefore we assayed this element
for GnRH responsiveness in vitro using LβT2 gonadotrope cells (Fig. 10, panel A). To map
the GnRH-responsive regions within this promoter fragment, 5′-deletions were generated and
tested using transient transfection assays. This analysis identified two distinct loci (Fig. 10B),
a distal region mapped between −692 to −626 bp, which was named the upstream response
region (URR), and a proximal promoter (PP) region mapped within −320 bp of the transcription
start site. The intervening DNA region between −626 and −320 may contain a negative
regulatory cis-acting DNA element, because successive 5′-deletions appeared to restore GnRH
responsiveness to the PP. To further test whether the URR and PP were independently GnRH
responsive, another series of 5′-deletion constructs were engineered upstream of a luciferase
reporter. Because luciferase reporter assays are more sensitive than β-galactosidase, small
changes in reporter activity can be easily measured. These constructs were transiently
transfected and treated with GnRH (Fig. 10C). Deletion of the PP, but retaining the URR
(URRΔPP1; −692 to −322 bp) and the proposed negative regulatory DNA sequence, failed to
produce a significant GnRH response, but deletion of the DNA sequence between −630 and
−322 bp (URRΔPP2; −692 to −630 bp) restored GnRH responsiveness to the URR. Further
deletion of the −320-bp fragment, by removing an additional 183 bp localized the PP to within
−136 bp. This short DNA fragment contains DNA binding and transactivation sites for SF-1
and Pitx1 (35,36) and encodes two putative Egr-1 DNA binding sites (37). Deletion of the
−136-bp region to −29 bp abolished GnRH-induced activity, confirming the importance of the
encoded transcription factor binding sites. Together, these data indicate that the URR and PP
are independent GnRH-response regions separated by a negative cis-acting regulatory element.
Regulation of the LH β-Subunit Gene Promoter by MAPK
To determine which GnRH-induced MAPK signaling response was required for function of
the URR and PP, we selected three constructs encoding −692, −320, and −136 bp and compared
responses after GnRH stimulation and after selective blockade of the various MAPK signaling
cascades (Fig. 11, A-D). Treatment with the c-Src inhibitor PP2 reduced promoter activity by
50% (Fig. 11A). Pretreatment with the specific MEK1/2 inhibitor PD98059 or cotransfection
of a dominant-negative MEK (dnMEK) plasmid indicated that the GnRH-induced ERK-
signaling response occurred via the PP (Fig. 11, B and D). Inhibition of JNK/p38MAPK using
high doses of SB203580 significantly repressed output across the promoter (Fig. 11B), but
addition of a different JNK/p38MAPK inhibitor SB202190, at lower doses (1–10 μM) blocked
the PP (Fig. 11C). The JNK/p38MAPK inhibitors, SB203580 and SB202190, can inhibit both
JNK and p38MAPK at high doses, but only inhibit p38MAPK at low doses (38). Cotreatment
with PD98059 and SB203580 significantly repressed output from the −320 and −136 bp
promoters when compared with PD98059, indicating that MEK1/2 and p38MAPK signaling
converged on the PP. Collectively, we deduced that the −692-bp promoter encoding the URR
was sensitive to high doses of JNK/p38MAPK inhibitor, suggesting that JNK signaling was
important, and that the PP was sensitive to blockade of c-Src, p38MAPK, and ERK.
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MAPK Regulation of Egr-1 Expression and DNA Binding
The studies indicate that the PP contains important regulatory elements that mediate GnRH-
dependent activation via the ERK and p38MAPK pathways. Egr-1 protein is a dynamic effector
of GnRH stimulation of the LH β-subunit gene promoter, is highly regulated by GnRH acting
via PKC and ERK in αT3-1 cells, and is required for LH β-subunit gene expression in vivo
(25,39-43). To examine whether Egr-1 was the actual target of the MAPK-regulated GnRH-
response in LβT2 cells, we assayed Egr-1 levels after hormone and MAPK inhibitor treatment.
The MEK1/2 inhibitor PD98059 completely blocked GnRH stimulation of Egr-1; in contrast,
treatment with p38MAPK inhibitor SB202190 at a concentration that previously inhibited
GnRH stimulation of the PP (Fig. 11C) had no effect on GnRH stimulation of Egr-1 levels
(Fig. 12, panel B). We then did a pull-down assay using the two putative Egr-1 DNA binding
sites encoded in the PP (Table 1) followed by Western blot analysis. Egr-1 bound the proximal
(pEgr-1) −55/−32 and not the distal (dEgr-1) −114/−91 binding site (Fig. 12C). We could not
detect any direct binding of Egr-1 to the dEgr-1 DNA binding site using this assay (data not
shown), but binding of Egr-1 to the pEgr-1 DNA binding site was specific because binding
was competed by wild-type pEgr-1 and not mutated mpEgr-1 double-stranded oligonucleotides
(Fig. 12C). Pretreatment of LβT2 cells with MAPK inhibitors blocked Egr-1 DNA binding
activity in the isolated nuclear extracts (Fig. 12D). This demonstrates that the PP contains one
high-affinity pEgr-1 binding site and that DNA binding of Egr-1 is regulated by MAPK.
MAPK Regulates Egr-1 Activation of the LH β-Subunit Promoter
The regulatory role of Egr-1 transactivation of the PP was further investigated by point
mutation of each DNA binding site to generate single and double distal and proximal mutated
PP (mutated distal Egr-1, mdEgr-1; mutated proximal Egr-1, mpEgr-1; mutated distal proximal
Egr-1, mdpEgr-1). These were stimulated in a series of transient transfection assays with GnRH
and treated with a combination of either PD98059 or SB202190 or both (Fig. 13A). GnRH
stimulated similar levels of expression of the PP and mdEgr-1, and inhibitor blockade indicated
that promoter response was marginally impaired by mutation of the distal site. In contrast,
GnRH failed to induce either the mpEgr-1 or mdpEgr-1 point-mutated construct; consequently,
further addition of MAPK inhibitors had no significant effect. Thus, this indicated that the
pEgr-1 DNA binding site dominantly regulated promoter activity. Cotransfection of a
constitutively expressed Egr-1 induced high levels of PP basal gene expression, which was
further augmented by addition of GnRH. But addition of either PD98059 or SB202190 or both
abrogated this GnRH-induced stimulation of Egr-1 activity (Fig. 13B). Coexpression of Egr-1
with the md- and mpEgr-1 constructs did not induce high levels of basal promoter activity, but
further addition of hormone did. The mdpEgr-1 promoter was refractory to both Egr-1 and the
combination of Egr-1 and GnRH. Addition of the MEK1/2 and/or p38MAPK inhibitors
blocked GnRH induction of Egr-1 transcriptional activity of both md- and mpEgr-1, but had
no effect on mdpEgr-1. These data show that both ERK and p38MAPK augment Egr-1
transcriptional activity, and that Egr-1 transactivates the PP very weakly via a distal site and
strongly via a proximal DNA binding site and is the main effector of GnRH-induced ERK-
regulated transcriptional modulation of the PP.
DISCUSSION
In the present study we have shown that GnRHR activation results in the formation of a Pyk2-
dependant multiprotein superstructure, which facilitates the activation of the ERK isoform of
the MAPK family. This triggers nuclear translocation of active ERK that is decoded into
transcriptional activation of the LH β-subunit gene promoter. Egr-1 was shown to be the ERK-
regulatory target by modulation of transcriptional activity and DNA binding, mainly mediated
via a proximal Egr-1 DNA binding site. Altogether, we have mapped a new ERK-signaling
route from activation of GnRHR to activation of transcription.
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We have shown that GnRH-induced ERK activation is rapid and prolonged in both αT3-1 and
LβT2 cells and is proximal in a hierarchical signaling response that, in contrast to a recent
report, does not occur through an EGFR-based mechanism (20). This discrepancy may be due
to our use of a physiological 10 nM GnRH concentration to activate ERK; doses in excess of
200 nM will also activate ERK (20), but gonadotrope cells can desensitize the ERK-induced
transcriptional apparatus if GnRH exceeds 100 nM (18,21). Hence, we observed no cross talk
between EGFR and GnRH, because inhibition of the EGFR intrinsic kinase failed to attenuate
GnRH-induced ERK activation, and there was negligible GnRH-induced tyrosine
autophosphorylation of the EGFR. Thus, these data agree with others that EGFR does not
contribute to the GnRH-induced ERK-signaling response in gonadotrope cells (5,19) and
suggest that if EGFR cross talk is not the primary mode of MAPK activation (7), then the
structural integrity of the cell cytoskeleton is key (9,11,44).
In this study GnRH-induced ERK activation appeared to contain cytoplasmic calcium and
tyrosine kinase-dependent components. Although others have shown increased FAK activity
in αT3-1 cells, this was not linked to ERK activation (5), and we noted only minimal activation
of FAK in both αT3-1 and LβT2 cells; therefore FAK was excluded as a major ERK target in
these cells. Because the FAK-related calcium-dependent tyrosine kinase Pyk2 is involved in
ERK activation by many different types of GPCRs (7,12,45,46), we further investigated the
role of this scaffolding protein in ERK activation. The tyrosine phosphorylation of Pyk2 and
the sensitivity of the GnRH-induced ERK signal to disruptors of the actin cytoskeleton
indicated that the ERK-activating signal was being transmitted through focal adhesion
complexes. Chelation of intracellular calcium using BAPTA-AM perturbed Pyk2 activation
and downstream ERK phosphorylation, supporting a role for Pyk2. The requirement for
calcium in activation of ERK in gonadotropes is variable (13,47). This may reflect the different
culture conditions used: we used low levels of serum and added GnRH, compared with serum-
free conditions favored by others; this explains the difference in the level of ERK stimulation
and possibly the reported degree of calcium dependence (13).
There was a clear relationship between ERK activation and tyrosine autophosphorylation of
Pyk2: the two events were sensitive to the same panel of intracellular signaling pathway
chemical inhibitors. In addition, GnRH induced the coassociation of Pyk2 with the downstream
signaling factors, c-Src and Grb2. Grb2 is a bifunctional signaling adapter molecule possessing
both Src homology-2 and -3 (SH2 and SH3) domains. The Ras-guanine nucleotide exchange
factor GEF mSos associates exclusively with Grb2, and overexpression of dominant-negative
forms of Pyk2 that were catalytically inactive or could not bind c-Src or Grb2 inhibited the
ability of GnRH to activate ERK. Furthermore, we noted that a GnRHR-stimulated focal
adhesion-based mechanism was required to induce nuclear translocation of activated ERK.
Taken together, these findings suggest that a multiprotein signaling complex assembles,
comprising Pyk2, c-Src, and some components of the MAPK pathway, i.e. Grb2-Sos and ERK,
and is dependent upon a functional actin cytoskeleton for selective translocation to the nucleus.
The nuclear locus of action for ERK was mapped and characterized as one of two GnRH-
activated cis-acting DNA regions in the LH β-subunit promoter, the URR (−692 to −626 bp)
and the PP (−136 to −29 bp). The URR was independently transcriptionally active from the
PP and appeared to be regulated by JNK. The PP was important for regulation of an integrated
GnRH response, because at this locus, inhibition of ERK and p38MAPK was additive,
indicating convergence of distinct signal transduction pathways. ERK and p38MAPK could
activate known or unknown transcription factors, and although the PP is activated by SF-1 and
Pitx1 (35,36), levels do not alter in response to GnRH treatment (40,48), but they may be post-
translationally modified (29,30).
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Therefore, because the PP encodes two putative Egr-1 DNA binding sites (37), we speculated
that Egr-1 was the main effector of GnRH-activated ERK- and p38MAPK-mediated
transcriptional regulation. In αT3-1 cells Egr-1 is induced by GnRH treatment (39,40,49,50),
the gene promoter of Egr-1 is regulated by ERK (41), and several coregulatory proteins
facilitate Egr-1 activation of the LH β-subunit gene promoter (51,52). In LβT2 cells both Egr-1
gene expression and DNA binding were regulated by ERK and p38MAPK, and only the pEgr-1
site actually bound protein in a pull-down assay. Pull-down assays are specific, because
proteins can adopt a native conformation when binding DNA and EMSA of the pEgr-1 and
dEgr-1 DNA binding sites in multiple species determined that the binding affinity of Egr-1 is
considerably higher for the proximal than the distal DNA binding site (53). Point mutation of
the Egr-1 DNA binding sites within the PP showed that pEgr-1 was crucial for promoter
activation after GnRH stimulation and after cotransfection of a constitutively expressed Egr-1
construct. Egr-1 transcriptional activity could be blockaded by ERK and p38MAPK inhibitors
or by mutation of the pEgr-1. In contrast, the dEgr-1 DNA binding site accounted for a very
small proportion of promoter activity and operated as an ancillary site. GnRH signaling induces
Egr-1 gene expression and transcriptional activity in immature αT3-1 cells (28,41); in
nongonadotrope cells Egr-1 is an immediate early gene regulated mainly by de novo induction
of gene expression (54) but can be differentially phosphorylated or acetylated according to the
stimulatory input (55-57). In mature LβT2 cells, we find that ERK and p38MAPK converge
to regulate the DNA binding and transcriptional activity of Egr-1. Interestingly, cofactor p300
regulates Egr-1 signaling in prostate cells and is known to interact with Egr-1 in gonadotrope
cells (52,57).
We have demonstrated that GPCR-mediated ERK activation by a focal adhesion-based
mechanism controls the generation of a transcriptionally active, nonmitogenic pool of activated
ERK (Fig. 14). In these gonadotrope cells, GnRHR stimulates immediate assembly of an ERK-
activating Pyk2 scaffold that requires a functional actin cytoskeleton to translocate it to the cell
nucleus, where it exerts a transcriptional effect to differentially regulate the output of the LH
β-subunit gene via Egr-1.
MATERIALS AND METHODS
Materials
The actin filament disruptors, cytochalasin D and latrunculin B, were obtained from
Calbiochem (Merck Biosciences, Beeston, UK). GnRH, epidermal growth factor (EGF), and
synthetic RGDS/RGES peptides and anti-Flag M2 agarose were obtained from (Peninsula
Laboratories, St. Helens, UK; or Sigma, Dorset, UK). The c-Src inhibitor 4-amino-5-(4-
cholorophenyl)-7-(t-butyl)pyrazolo[3,4-D]pyrimidine (PP2) and the chemical inhibitors
genistein, PD98059, SB203580, SB202190, Ro31–8220, BAPTA-AM, and wortmannin were
all obtained from Calbiochem. The cDNAs encoding the mutant Pyk2 constructs were donated
by Ivan Dikic. Dominant-negative Raf and Ras constructs were donated by Ulf Rapp, and
dominant-negative MEK and JNK are described in Refs. 5,58, and 59). The myc-tagged ERK2
construct was obtained from Eisuke Nishida, Kyoto University.
Generation of Constructs
The ovine LH β-subunit gene promoter 5′-flanking sequence −1000, −692, −626, −536, and
−320-bp constructs were generated by Exonuclease III digestion of −1786-bp fragment (34)
and were ligated upstream of a Lacz reporter in pnLacF (60). The pA3Luc luciferase reporter
(a gift from Dr. David Gordon, Denver, CO) construct −692 was prepared using −1786 pnLacF
as a template using Extensor Long PCR master mix (Abgene, Epsom, UK) and primer pair
oS1/oAS1 (Table 1). Point-mutated constructs were generated by PCR using appropriate
primer combinations mpEgr-1 (oS2/omAS2), mdEgr-1 (omS2/oAS2), and mdpEgr-1 (omS2/
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omAS2) and incorporated into a larger fragment by additional denaturing, annealing, and
priming cycles using an internal overlap with a 74-bp (oCS2/oACS2) fragment (Table 1). The
resultant PCR products were cloned into pCRII vector (Invitrogen Ltd., Paisley, Scotland, UK)
and excised with KpnI/HindIII or appropriate restriction enzymes and ligated into pA3Luc.
Promoter constructs −320, −136, UrrΔPP1, URRΔPP2, and the minimal promoter (−29) were
cloned into pA3LUC using defined restriction sites and standard methods. The Egr-1 protein
expression construct was made as follows: the two individual exons of Egr-1 were amplified
by PCR from 1 ng of human genomic DNA using exon-specific primers (Table 1). These PCR
products were denatured and annealed using the introduced FLAG tag before amplification by
PCR using the Egr-1ex1S and Egr-1ex2AS primers and cloned into pCDNA 3.1 (Invitrogen
Ltd.). The reading frame and integrity of the Egr-1 construct were checked by in vitro
translation using a TNT-coupled wheat germ extract (Promega UK, Ltd., Southampton, UK)
according to manufacturer's instructions. All constructs were verified by DNA sequencing.
Cell Culture and Transfection
Murine αT3-1 and LβT2 gonadotrope cells were provided by Professor Pamela Mellon (San
Diego, CA) and cultured as described elsewhere (32). To serum deprive gonadotropes, cell
monolayers were incubated with DMEM supplemented with 0.5% fetal bovine serum for 16
h. Transient transfections were either performed using Superfect (Qiagen House, Crawley, UK)
as described previously (61) or were carried out as described in Refs. 21 and 36. Lacz
transfections used chloramphenicol acetyl transferase (CAT) plasmid pCMV-CAT as an
internal control for transfection efficiency. Human Egr-1/pCDNA3.1 expression vector was
cotransfected at a ratio of 1:200; dnMEK was cotransfected at a ratio of 1:10. After 48 h the
cells were treated for a further 6 h with 100 nM GnRH or were left untreated. Chemical
inhibitors were added for the time periods specified in the figure legends before agonist
stimulation. CAT activity was determined as described elsewhere (34), and Lacz activity was
measured using a kit (Roche Diagnostics). Reporter activity was measured as described
previously (21,36). The total reporter gene activity normalized against internal reference
activity was taken as 1, and results were calculated as fold activation by GnRH over untreated
levels. Data are presented as the mean ± SEM. Statistical significance was determined using one-
way ANOVA, with a value of P < 0.05 considered significant.
Measurement of MAPK Phosphorylation
Specific ERK1/2 or myc-ERK2 phosphorylation was measured as previously described (8,9).
Visualization of alkaline phosphatase-labeled proteins was performed using enzyme-linked
chemifluorescence (Amersham Pharmacia Biotech, Little Chalfont, UK) and quantified using
a Storm 860 Phosphorimager. In Fig. 2 LβT2 cells were stimulated with GnRH and then treated
essentially as described elsewhere (18), except 30-μg sample aliquots were separated on 10%
SDS-PAGE, followed by Western blotting with mouse monoclonal anti-phospho MAPKs (5,
16). Total MAPKs were detected with polyclonal antibodies for the various MAPKs as a control
for sample loading.
Immunoprecipitation, Immunoblotting, and Egr-1 Pull-Down Assay
After stimulation cell monolayers were placed on ice, washed twice in ice-cold Dulbecco's
PBS (DPBS), nuclear proteins were harvested as described (36), and a 25-μg aliquot of this
was fractionated by SDS-PAGE. Alternatively, if total protein extracts were required, the cells
were washed and then lysed in an Nonidet P-40-based solubilization buffer (8), clarified by
centrifugation at 10,000 × g for 15 min, and diluted to 1 mg/ml of total protein. A 50-μl aliquot
of clarified lysate was mixed with an equal volume of 2× Laemmli sample buffer and resolved
by SDS-PAGE for confirmation of plasmid expression or determination of intracellular protein
activation by protein immunoblotting.
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Phosphotyrosine proteins were immunoprecipitated with 20 μl of a 30% slurry of anti-PY20
agarose preconjugated antisera (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) with
agitation for 16 h at 4 C. Pyk2 was immunoprecipitated using 1 μg of mouse antihuman Pyk2
monoclonal antisera (BD Biosciences, Oxford, UK) with 25 μl of a 50% slurry of protein G-
plus/protein A agarose with agitation for 16 h at 4 C, Grb2 was immunoprecipitated with 2
μg of rabbit antihuman Grb2 polyclonal antisera (Santa Cruz), and 25 μl of the protein G-plus/
protein A agarose with agitation for 16 h at 4 C. Myc-epitope-tagged proteins were
immunoprecipitated with 25 μl of a 30% slurry of anti-myc agarose preconjugated antisera
(Santa Cruz) with agitation for 16 h at 4 C. Immune complexes were detected as described
previously (9).
Endogenous epidermal growth factor receptor (EGFR) was detected using a 1:1000 dilution
of a rabbit antimouse EGFR polyclonal IgG (Santa Cruz), Grb2 was detected with a 1:1000
dilution of a rabbit antihuman Grb2 polyclonal IgG (Santa Cruz), and Egr-1 was detected by
a 1:5000 dilution of a rabbit antihuman polyclonal IgG (Santa Cruz). Both EGFR and Grb2
used a 1:15,000 dilution of alkaline phosphatase-conjugated polyclonal antirabbit as a
secondary antibody (Sigma). For Egr-1 a 1:20,000 dilution of horseradish peroxidase-
conjugated swine antirabbit IgG was used, and proteins were visualized as described (62).
Tyrosine-phosphoproteins were detected using a 1:1000 dilution of a mouse antimouse PY99
(Santa Cruz) and a 1:15,000 dilution of alkaline phosphatase-conjugated polyclonal antimouse
as a secondary antibody (Sigma).
For Egr-1 pull-down assays, 250 μg of M280 streptavidin Dynabeads (Dynal Biotech Ltd.,
Wirral, UK) were mixed with 20 pmol of biotinylated distal (d) or proximal (p) Egr-1 double-
stranded DNA oligonucleotides (Table 1) at room temperature for 1 h. Unbound DNA was
washed off before addition of 150 μg of LβT2 nuclear extract in binding buffer 1 (20 mM Tris-
HCl, pH 7.9; 50 mM NaCl; 10% glycerol; 1 mM EDTA, pH 8.0; 1 mM dithiothreitol) with
Complete protease inhibitors (Roche Diagnostics). Where appropriate, a 25-fold excess of
nonbiotinylated competitor double-stranded oligonucleotide was preincubated with the nuclear
extract. The binding reactions were incubated with constant rocking at 4 C for 4 h, after which
excess protein was washed off, and bound complexes were eluted in 10 μl of 0.25M NaCl and
0.0125% SDS, resolved by SDS-PAGE, and detected by Western blotting.
Immunocytochemistry and Confocal Microscopy
Confocal microscopy was performed using a Zeiss LSM510 laser-scanning microscope using
a 63 × 1.4 numerical aperture oil immersion lens. LβT2 cells were stimulated for the time
periods specified in the appropriate figure legends with GnRH (10 nM) at 37 C. After
stimulation, the cells were washed in DPBS, fixed in 100% methanol (MeOH) at −20 C for 10
min, permeabilized at room temperature using DPBS supplemented with 1% BSA and 0.2%
NP-40 for 30 min and eventually mounted in Permafluor (Immunotech). The permeabilized
cells were then blocked for 1 h with a 1% BSA-DPBS solution. After blocking, the
permeabilized cells were then incubated for 1 h with a 1:200 dilution of a rabbit antiactive
ERK1/2 followed by an antirabbit fluorescein isothiocyanate-conjugated secondary (1:100
dilution).
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Fig 1. Sustained ERK Activation in Gonadotrope Cell Lines
GnRH stimulation of αT3-1 or LβT2 cells results in a rapid elevation of the cellular amount of
the active form of the ERK1/2 MAPK isoform. A, Representative antiactive ERK1/2 Western
blot of 2% of whole-cell extract from LβT2 cells. B and C, Histograms of mean ± SEM data from
at least four individual measurements of GnRH-induced ERK1/2 activation in αT3-1 and
LβT2 cells. IB, Immunoblot; W.C. LYS, whole-cell lysate.
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Fig 2. MAPK Activation in LβT2 Gonadotrope Cell Line
GnRH stimulation of LβT2 cells activates MAPK signaling in the form of ERK1/2 and JNK1/2
isoforms and p38MAPK and c-Src. A, Representative antiactive ERK1/2. α-DP, Anti-
diphospho; α-G, anti-general. B, Rapid elevation of antiactive JNK1/2 for comparison. C,
Induction and time course of activation of active p38MAPK. D, Activation of c-Src over the
same time frame as panels A–C. In each experiment a Western blot of 2% of whole-cell extract
from LβT2 cells was used. Panels B–D used p38MAPK as a loading control, whereas panel A
used the nonactive form of ERK1/2. The panels shown are representative of three separate
experiments.
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Fig 3. GnRHR Activation Mediates ERK1/2 Activation Independently of EGFR Kinase Activity
A, EGF (10 ng/ml, 10 min) but not GnRH (10 nM, 10 min) elevated the tyrosine phosphorylation
status of the immunoprecipitated EGFR in both αT3-1 and LβT2 cells. Preincubation of αT3-1
and LβT2 cells with tyrphostin AG1478 inhibited EGF (10 ng/ml, 10 min)-induced EGFR
tyrosine phosphorylation. AG1478 pretreatment effectively inhibited EGF-induced but not
GnRH-induced ERK1/2 activation. The effects of GnRH and EGF upon EGFR tyrosine
phosphorylation in αT3-1 and LβT2 cells are quantified in panels B and C, respectively. Each
bar in the histograms in panels B and C depict mean ± SEM data values for the degree of both
ERK1/2 activation and EGFR tyrosine phosphorylation by EGF and GnRH in the presence or
absence of AG1478 from three separate experiments. IB, Immunoblot; IP,
immunoprecipitation; NS, nonstimulated; w.c. LYS, whole-cell lysate.
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Fig 4. Chemical Sensitivity of ERK1/2 Activation in Gonadotrope Cells
Both αT3-1 (panel A) and LβT2 cells (panel B) were preincubated with BAPTA-AM (50 μM,
30 min), phorbol 12-myristate-13-acetate (1 μM, 16 h), Ro-31 8220 (100 nM, 60 min),
cytochalasin D (1 μM, 60 min), latrunculin B (1 μM, 60 min), herbimycin-A (1 μM, 60 min),
tyrphostin AG1478 (100 nM, 30 min), PP2 (1 μM, 30 min), and wortmannin (10 nM, 30 min)
before a 10-min stimulation with 10 nM GnRH. A similar general pattern of chemical inhibitor
sensitivity was observed between αT3-1 and LβT2 cells. Hence, on both cell types the GnRH-
induced ERK1/2 activation appeared to be dependent upon intracellular Ca2+ elevation, PKC
activity, intact cytoskeletal structure, and c-Src tyrosine kinase activity yet relatively
insensitive to inhibition of EGFR tyrosine kinase activity or phosphatidylinositol 3-kinase
activity. In both panels A and B, each bar in each histogram represents the mean ± SEM of three
individual experiments.
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Fig 5. GnRHR Activation Induces the Activation of the FAK Pyk2 in Gonadotrope Cells
A and B, Representative Western blots of antiphosphotyrosine immunoprecipitates (PY20)
probed with an antisera also against phosphotyrosine residues (PY99). In both panels several
proteins can be identified increasing in their phosphotyrosine content in response to GnRH,
but the most profoundly affected protein migrates with a mass close to the β-galactosidase 115-
kDa molecular mass marker. GnRH stimulation resulted in a time-dependent increase in the
degree of tyrosine phosphorylation of directly immunoprecipitated Pyk2 (panel C, αT3-1: panel
D, LβT2). The bars in each histogram in panels C and D represent the mean ± SEM of three
individual Pyk2 immunoprecipitation experiments. GnRH-mediated elevation in Pyk2 tyrosine
kinase activity was efficiently inhibited by PP2 (1 μM, 30 min), BAPTA-AM (50 μM, 30 min),
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Ro-31 8220 (100 nM, 60 min), and cytochalasin D (1 μM, 60 min), but not by tyrphostin AG1478
(100 nM, 30 min) pretreatment. Pyk2 activation demonstrates a similar chemical sensitivity to
the ERK1/2 activation pathway and occurs largely independently of EGFR activity. Each
bar in the histogram represents the mean ± SEM of at least three individual experiments. IB,
Immunoblot; IP, immunoprecipitation; NS, nonstimulated.
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Fig 6. Focal Adhesion Dependence of GnRH-Induced Pyk2 and ERK1/2 Activation
LβT2 cells were pretreated with either 1 mM RGDS or 1 mM RGES for 16 h before EGF (10
ng/ml, 10 min) or GnRH stimulation (10 nM, 10 min). A, RGDS abrogated GnRH-induced, but
not EGF-induced, ERK1/2 and activation. Preincubation with the control RGES tetrapeptide
had no effect on either GnRH- or EGF-induced ERK1/2 activation. RGDS pretreatment
attenuated GnRH-induced Pyk2 tyrosine phosphorylation, whereas RGES had no effect. EGF
stimulation failed to alter the tyrosine phosphorylation status of immunoprecipitated Pyk2. The
histograms in panel B and C depict mean ± SEM. ERK and Pyk2 phosphorylation data are from
at least three separate experiments. IB, Immunoblot; IP, immunoprecipitation; w.c., whole cell;
NS, nonstimulated.
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Fig 7. GnRH-Induced Association of Pyk2 with Downstream Signaling Intermediates
A, Representative Western blot for the c-Src content of Pyk2 immunoprecipitates from LβT2
cells. With GnRH stimulation there is a time-dependent association between c-Src and Pyk2.
B, GnRH-induced c-Src and Pyk2 association is inhibited by cytochalasin-D, latrunculin-B,
and herbimycin-A. GnRH induces a dynamic elevation of the relative Grb2 content of Pyk2
immunoprecipitates (panel C). GnRH stimulation also induces a dynamic elevation of the
relative Pyk2 content of Grb2 immunoprecipitates (panel D). GnRH stimulation induces a
dynamic elevation of the relative tyrosine-phosphorylated-Pyk2 content of Grb2
immunoprecipitates (panel E). The associated histograms display mean ± SEM data of at least
three individual experiments. cyto-D, Cytochalasin-D; herb-A, herbimycin-A; IB,
immunoblot; IP, immunoprecipitation; lat-B, latrunculin-B; NS, nonstimulated.
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Fig 8. Activation of ERK1/2 Requires Protein Complex Assembly at the Pyk2 Tyrosine Kinase and
Occurs via a Canonical Ras-Dependent Cascade
GnRH stimulation (10 nM, 10 min) elevated the degree of active transiently transfected myc-
tagged ERK2 (panel A). Cotransfection with a kinase-deficient (K475A), a c-Src binding-
deficient (Y402F), and a Grb2 binding-deficient form of Pyk2 (Y881F) inhibited GnRH-
mediated activation of the myc-ERK reporter. The associated histograms (panel B) represent
the mean ± SEM of myc-ERK2 activations gathered from four individual experiments. In panel
C, GnRH-induced (10 nM, 10 min) activation of myc-ERK2 was also abrogated when dominant-
negative Ras (N17Ras) or Raf (Raf-C4B) were coexpressed. Pretreatment with the chemical
MEK1/2 inhibitor PD98059 (20 μM, 60 min) before GnRH stimulation also significantly
reduced the GnRH-induced myc-ERK2 activation. The histogram in panel D depicts mean ±
SEM ERK2 activation data gathered from four individual experiments performed as in the
Western blot (panel C). IB, Immunoblot; IP, immunoprecipitation.
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Fig 9. GnRH Mediates the Time-Dependent Activation of ERK1/2 in the Gonadotrope Nucleus
GnRH stimulation of LβT2 cells (10 nM, ≤90 min) resulted in the generation of an increase in
the cellular antiactive ERK1/2 immunoreactivity. The images in panel A depict representative
confocal laser images from permeabilized LβT2 cells stained for antiactive ERK1/2. In the
absence of ligand (images 1–2) there is minimal activated ERK1/2 staining; however, with 10
min of 10 nM GnRH stimulation there appears to be an increase in the cytoplasmic active
ERK1/2 staining and the generation of an annular nuclear staining pattern (images 3–8). In
panel B (images 5–8), the degree of nuclear active ERK1/2 is significantly attenuated when
the cells were pretreated with cytochalasin-D (1 μM) or latrunculin-B (1 μM). cyto-C,
Cytochalasin-D; lat-B, latrunculin-B; FITC, fluorescein isothiocyanate.
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Fig 10. Mapping GnRH-Responsive Regions in the LH β-Subunit Promoter
A, 6 h of GnRH (100 nM) treatment of LβT2 cells induced the optimal GnRH response in a
transfected −1786 ovine LH β-subunit gene promoter fragment ligated to a β-galactosidase
(Lacz) reporter vector. Results are presented as fold induction of promoter activity by GnRH,
calculated as Lacz/CAT (internal control) levels in untreated cells (−), expressed as 1,
compared with the same construct in treated cells (+). B, GnRH treatment of a series of 5′-
promoter resections identified a distal URR between −692 and −626 bp and a proximal region
(PP) bounded by −320 bp. Results were calculated as described above. C, Internal deletion
analysis of the −692-bp LH promoter ligated to a luciferase (LUC) reporter identified that the
URR was independently responsive to GnRH. Hence, the URR and PP were mapped to −692/
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−626 and −136 bp, respectively, and a negative regulatory cis-acting element was identified
between −630 and −322 bp. Each panel is the average of at least three experiments, each done
in triplicate. Significant differences were calculated using one-way ANOVA. *, P < 0.05; **,
P < 0.01; and ***, P < 0.001 untreated vs. treated, except where indicated. Results are expressed
as the mean ± SEM.
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Fig 11. Differential MAPK Signaling to the LH β-Subunit Gene Promoter
A–C, LH β-subunit promoter constructs corresponding to −692 (URR and PP), −320 (PP), and
−136 (PP) were transfected into LβT2 cells, pretreated with inhibitor where indicated, and
either left untreated or treated with GnRH and incubated for a further 6 h. Luciferase levels
were corrected for transfection efficiency and adjusted to 1 for untreated controls. Black
bars correspond to control GnRH-treated, whereas white bars depict GnRH+drug. D,
Constructs detailed above were cotransfected with 1:10 dnMEK expression plasmid; white and
gray bars are treated with GnRH; striped and gray bars were cotransfected. One-way ANOVA
identified the following: ***, P < 0.001; **, P < 0.01; and *, P < 0.05 as statistically significant
from GnRH treated in panels A–D. GnRH fold stimulation is shown for each construct and
was calculated from at least three separate experiments, each done in triplicate and expressed
as mean ± SEM. Statistical differences within treatment groups are also indicated where relevant.
A, GnRH transactivation of the LH β-subunit promoter is uniformly and significantly inhibited
by the tyrosine kinase inhibitor PP2 at 10-μM concentrations. Inhibitor PP2 was added 30 min
before GnRH in increasing concentrations (1, 5, and 10 μM). B, 30-min pretreatment with
MEK1/2 inhibitor PD (PD98059, 20 μM) confirmed the sensitivity of the PP and indicated that
inhibition of p38MAPK/JNK by SB (SB203580, 30 μM) was additive at this site. In panel C
the response to increasing concentrations of JNK/p38MAPK inhibitor SB202190 (1, 5, and 10
μM) showed that the −692 promoter encoding the intact URR was less sensitive to JNK/
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p38MAPK inhibition than the PP. D, Cotransfection with dnMEK mapped the ERK response
to the PP.
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Fig 12. Egr-1 is the Transcription Factor Target of ERK-Mediated Signaling
LβT2 cells were left untreated (−) or treated with GnRH and/or either PD98059 or SB202190
(+) and nuclear proteins harvested 2 h later. A and B, Nuclear protein (25 μg) was size
fractionated and Egr-1 expression detected with anti-Egr-1 antisera. Treatment of LβT2 cells
with 50 μM specific MEK1/2 inhibitor PD98059, but not 5 μM p38MAPK inhibitor SB202190,
blocks GnRH activation of Egr-1 protein expression. C and D, Nuclear extract (150 μg) was
incubated with streptavidin-immobilized double-stranded biotinylated oligonucleotides
encoding the proximal Egr-1 (pEgr-1) binding site for 4 h at 4 C. Unbound competitor (UC)
wild-type and mutant (m) double-stranded oligonucleotides were incubated with nuclear
proteins at 25-fold excess. Complexes were then eluted and resolved by SDS-PAGE before
transferring to PVDF and probing with antisera to Egr-1. C, The pEgr-1 sequence specifically
bound Egr-1, which could be competed by wild-type but not mpEgr-1. D, The pEgr-1 DNA
binding site was incubated with nuclear extract (NE) that had been pretreated with 50 μM
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PD98059 or 5 μM SB202190 before addition of 100 nM GnRH. Inhibitor blockade also blocked
Egr-1 binding to pEgr-1. Each panel is representative of an experiment that was repeated two
times. Protein size markers are indicated in kilodaltons.
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Fig 13. Egr-1 Specifically Transactivates the PP
LβT2 cells were transfected with either an intact PP or one point mutated at one of two possible
Egr-1 DNA binding sites (indicated by a black cross), (mdEgr-1, mpEgr-1, and mdpEgr-1)
luciferase reporter vectors (panel A), and cotransfected with a constitutive Egr-1 expression
construct (panel B). Cells were then either left untreated or pretreated with MAPK inhibitors
(PD98059 50 μM, SB202190 5 μM, or both) as indicated before being stimulated with 100 nM
GnRH. A, GnRH induced a significant increase in luciferase levels that could be blocked by
pretreatment with MAPK inhibitors. Mutation of mpEgr-1 or mdpEgr-1, but not mdEgr-1,
blocked GnRH activation and rendered the inhibitors ineffective. B, Cotransfection of a
constitutively expressed Egr-1 expression construct (1:200) induced basal PP expression,
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which was augmented by GnRH. Pretreatment with MAPK inhibitors blocked GnRH-induced
transcriptional activation of Egr-1 but had no effect on Egr-1 stimulation of basal promoter
expression. Point mutation of either Egr-1 DNA binding site abrogated Egr-1-induced basal
promoter activity; however, addition of GnRH activated the mdEgr-1, partially rescued
mpEgr-1, and had no effect on mdpEgr-1. Consequently, MAPK blockade also mirrored this
hierarchy. Each panel is the average of three separate experiments each done in triplicate.
Significant differences within and between groups were determined by one-way ANOVA as
*, P < 0.05; **, P < 0.01; and ***, P < 0.001; and nonsignificant (NS) are indicated.
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Fig 14. Schematic Representation of GnRH-Induced Pyk2-Dependent ERK-Activated Signaling to
the LH β-Subunit Gene Promoter
Binding of GnRH to the GnRHR triggers an intracellular signaling cascade, which radiates
from activation of PKC. Tyrosine phosphorylation of Pyk2 and downstream activation of ERK
were blocked by general tyrosine kinase inhibitors herbimycin A (Herb A) and PP2, by
chelation of intracellular calcium release with EGTA/BAPTA, and by inhibition of PKC by
Ro-31–8220. Addition of cytoskeletal inhibitors cytochalasin-D (cyto-D), latrunculin-B (lat-
B), and RGDS tetrapeptides, which disrupt focal adhesions, confirmed the association of Pyk2
tyrosine phosphorylation with ERK activation. GnRH induced a focal adhesion-anchored
signaling complex between c-Src and Pyk2, because Herb A, cyto-D, and lat-B all blocked the
association. Phosphorylated Pyk2 bound Grb2, and this association of Pyk2 activity, signaling
complex formation, and ERK activation was confirmed using point mutations of Pyk2.
Expression of a c-Src activation site mutant (Y402F) and mutation of the Grb2 binding site
(Y881F) in Pyk2 all abrogated activation of ERK. Using dominant-negative mutants and the
MEK1/2 inhibitor PD98059, we identified that the signaling complex activated Ras, c-Raf,
and MEK, which induced nuclear localization of ERK. The nuclear focus of this Pyk-2-
dependent ERK-activated pathway was Egr-1. Using PD98059, constitutively active Egr-1,
DNA resections, and point mutation of Egr-1 DNA binding sites within the LH β-subunit gene
promoter mapped ERK-responsive Egr-1 dependence to the PP and not the upstream response
region (URR). Broken lines indicate activation pathways elucidated by others (5,13,14,58,
63), whereas solid lines indicate direct activation demonstrated in this study and are described
above. Light blue boxes are labeled with the inhibitor and dominant negative mutants used and
are positioned at the appropriate point of the MAPK signaling cascade. PLC-β, Phospholipase
C-β.
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Table 1
Synthetic Oligonucleotides Used for Egr-1 Pull-Down and PCR Experiments
Name Position (bp) DNA Sequence (5′–3′)
pEgr-1 −55/−32 TGGCCTTGCCGCCCCCACAGCCTG
mpEgr-1 −55/−32 TGGCCTTGCCGCCCTTAGAGCCTGa
dEgr-1 −114/−91 GCCTCTCGCCCCCGGGGAGATTAG
mdEgr-1 −114/−91 GCCTCTAGTACTCGGGGAGATTAGa
oS2 −126/−100 CTGACCTTGTCTGCCTCTCGCCCCCGG
omS2 −126/−100 CTGACCTTGTCTGCCTCTAGTACTCGa
oAS2 −46/−22 CTTATACCTGCAGGCTGTGGGGGCG
omAS2 −46/−22 CTTATACCTGCAGGCTCTAAGGGCGa
oCS2 −35/−16 CCTGCAGGTATAAGACTAGG
oACS2 +19/pA3Luc CGGAATGCCAAGCTTAATTCGb
oS1 −692/−675 GGGGTACCAGATCTTGGCCCTTGGACb
oAS1 −20/+13 CCCCAACTTGCCTCCCCTGCTGTGTTCACCTAG
Egr-1ex1S −7/+14 GAGTCGCGAGAGATCCAGCCG
Egr-1ex1ASFLAG +572/+587 CTTGTCATCGTCGTCCTTGTAGTCTGCGGTCAGGTGCTCGc
Egr-1ex2SFLAG +1274/+1292 GACTACAAGGACGACGATGACAAGGAGTCTTTTCCTGACATCTCc
Egr-1ex2AS +2665/+2385 CTCCTCTCCTATGGCCATCTC
Nucleotide sequence numbering in base pairs (bp) is relative to the transcription start site of the ovine LH β-subunit gene or the human Egr-1 gene. PCR
primers are shown as sense (S) or antisense (AS). Putative Egr-1 DNA binding sites are underlined.
are highlighted in bold.
c
FLAG tag
b
HindIII and KpnI restriction enzyme sites
a
point mutations in pEgr-1 and dEgr-1 DNA binding site
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